Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Crawford Highlights Role of Degarelix in Prostate Cancer

March 24th 2017

E. David Crawford, MD, shares insight on incorporating ADT, specifically degarelix, into the prostate cancer landscape and why it remains to be a standard go-to approach for patients.

Dr. Dreicer on Abiraterone and Enzalutamide in Prostate Cancer

March 24th 2017

Robert Dreicer, MD, associate director for Clinical Research and deputy director of the University of Virginia Cancer Center, discusses abiraterone acetate (Zytiga) and enzalutamide (Xtandi) in metastatic castration-resistant prostate cancer (mCRPC).

Expert Discusses State of Immunotherapy in Prostate Cancer

March 23rd 2017

Susan F. Slovin, MD, PhD, discusses the current state of immunotherapy in prostate cancer.

Dr. Slovin on the Role of Immunotherapy for Prostate Cancer

March 22nd 2017

Susan F. Slovin, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the current role of immunotherapy in patients with advanced prostate cancer.

Dr. Abida on Genetic Testing for Prostate Cancer

March 21st 2017

Wassim Abida, MD, PhD, medical oncologist, Developmental Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses genetic testing for patients with prostate cancer.

Expert Sees Checkpoint and PARP Inhibitors Building on mCRPC Success

March 14th 2017

Paul G. Corn, MD, PhD, discusses recent advances in prostate cancer and the potential for immunotherapy and PARP inhibitors in the field.

Researchers Aim to Further Enhance Value of RT in Prostate Cancer

March 14th 2017

Seungtaek L. Choi, MD, discussed the latest developments with radiation therapy in prostate cancer.

Dr. Araujo on Emerging Data on Radium-223 for Patients With mCRPC

March 13th 2017

John C. Araujo, MD, PhD, assistant professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses emerging data with radium-223 dichloride (Xofigo) for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). Araujo shared this insight during the 2017 OncLive® State of the Science Summit on Genitourinary Cancers.

Gomella Discusses Ongoing Progress With Genetic Testing in Prostate Cancer

March 11th 2017

Leonard Gomella, MD, discusses the current state and critical next steps for optimizing genetic testing in prostate cancer.

Dr. Klein on Gene Mutations in Prostate Cancer

March 11th 2017

Eric Klein, MD, professor of Surgery, Lerner College of Medicine, Cleveland Clinic, discusses gene mutations in patients with prostate cancer.

Dr. Choi on Evolution of RT in Prostate Cancer

March 10th 2017

Seungtaek L. Choi, MD, an assistant professor in the Department of Radiation Oncology, and clinical Medical Director, Department of Genitourinary Medical Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, discusses how radiation therapy has evolved for the treatment of patients with prostate cancer.

Active Surveillance Remains a Critical Approach for Early Prostate Cancer

March 10th 2017

Brian F. Chapin, MD, discusses the importance of active surveillance in patients with prostate cancer at a low risk of developing metastases and the benefits of surgery and radiation as active treatment methods for patients with locally advanced disease.

Dr. Gomella on Challenges Facing Genetic Testing in Prostate Cancer

March 10th 2017

Leonard Gomella, MD, professor, chair, Department of Urology, director, Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses challenges facing genetic testing for patients with prostate cancer.

Dr. Corn on Sequencing Agents for Patients With mCRPC

March 10th 2017

Paul G. Corn, MD, PhD, associate professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the agents available to treat patients with metastatic castration-resistant prostate cancer (mCRPC)

Dr. Chapin on Choosing Active Surveillance for Patients With Prostate Cancer

March 10th 2017

Brian F. Chapin, MD, assistant professor, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses the considering factors for a patient with prostate cancer to undergo active surveillance versus active treatment.

Factors Influencing Patient-Reported Rectal Toxicity Following External Beam Radiation Therapy for Prostate Cancer

March 10th 2017

Developing and validating a predictive model for patient-reported health-related quality of life remains an elusive target, and one that has great potential to further improve satisfaction with outcome following prostate cancer treatment in a great number of prostate cancer survivors.

Combinations Key to Advances With Bone-Targeting Agents in mCRPC

March 9th 2017

John C. Araujo, MD, PhD, discusses targeted therapies, current and emerging, for patients with bone-metastatic castration-resistant prostate cancer.

Petrylak Discusses Significance of Genetic Testing in Prostate Cancer

March 8th 2017

Daniel Petrylak, MD, discusses the significance of genetics in the future of prostate cancer care and highlights emerging treatments and challenges in the field.

Dr. Araujo on Importance of Bone-Targeting Agents in mCRPC

March 8th 2017

John C. Araujo, MD, PhD, assistant professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the importance of bone-targeting agents for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). Araujo shared this insight during the 2017 OncLive® State of the Science Summit on Genitourinary Cancers.

Dr. Crawford on PSA Testing for Prostate Cancer

March 8th 2017

E. David Crawford, MD, professor of Radiation Oncology, University of Colorado School of Medicine, discusses challenges facing PSA testing for patients with prostate cancer.